Literature DB >> 22850219

Type 1 (sub-retinal pigment epithelial) neovascularization in central serous chorioretinopathy masquerading as neovascular age-related macular degeneration.

Adrian T Fung1, Lawrence A Yannuzzi, K Bailey Freund.   

Abstract

PURPOSE: The purpose of this study was to describe clinical and multimodal imaging features of patients with Type 1 neovascularization who lack findings of age-related macular degeneration but instead have features consistent with long-standing central serous chorioretinopathy (CSC).
METHODS: Nonconsecutive, retrospective, observational case series. Two groups of patients were identified and analyzed. Group 1 included patients presenting with Type 1 neovascularization who at the time of diagnosis were found to have findings more consistent with long-standing CSC than age-related macular degeneration. Group 2 included patients with a known history of CSC who developed Type 1 neovascularization over their course of follow-up. Clinical histories and multimodal imaging findings (color and red-free photography, fundus autofluorescence imaging, fluorescein angiography, indocyanine green angiography, spectral domain optical coherence tomography, and enhanced depth imaging optical coherence tomography) were analyzed.
RESULTS: Twenty-seven eyes of 22 patients were identified. Thirteen patients presented with Type 1 neovascularization thought to be secondary to CSC (Group 1), and 9 patients with CSC were observed to develop Type 1 neovascularization over their course of follow-up (Group 2). Eight patients (36%) had polypoidal neovascular structures within their Type 1 neovascular lesions, of which 4 (18% of all patients) had bilateral Type 1 neovascularization. The mean age of patients was 61 years (range, 48-76 years), and the median age was 58.5 years. Thirteen patients (59%) were men. For those patients in Group 2, the mean duration between diagnosis of CSC and detection of Type 1 neovascularization was 139 months (range, 7-365 months). The mean subfoveal choroidal thickness was 354 μm (range, 186-666 μm).
CONCLUSION: Some patients presenting with Type 1 neovascularization may have clinical and multimodal imaging findings more consistent with long-standing CSC than with age-related macular degeneration. These patients are more likely to be younger, men, have thicker choroids, and have a higher prevalence of polypoidal neovasculopathy than those patients with Type 1 neovascularization secondary to age-related macular degeneration. Proper identification of these patients may have implications for their natural course and management.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22850219     DOI: 10.1097/IAE.0b013e3182680a66

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  62 in total

1.  Classification of pachychoroid on optical coherence tomography using deep learning.

Authors:  Nam Yeo Kang; Ho Ra; Kook Lee; Jun Hyuk Lee; Won Ki Lee; Jiwon Baek
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-02-22       Impact factor: 3.117

2.  Association of Choroidal Neovascularization and Central Serous Chorioretinopathy With Optical Coherence Tomography Angiography.

Authors:  Marco Antonio Bonini Filho; Talisa E de Carlo; Daniela Ferrara; Mehreen Adhi; Caroline R Baumal; Andre J Witkin; Elias Reichel; Jay S Duker; Nadia K Waheed
Journal:  JAMA Ophthalmol       Date:  2015-08       Impact factor: 7.389

3.  The role of indocyanine green angiography imaging in further differential diagnosis of patients with nAMD who are morphologically poor responders to ranibizumab in a real-life setting.

Authors:  A Ozkaya; C Alagoz; R Garip; Z Alkin; I Perente; A T Yazici; M Taskapili
Journal:  Eye (Lond)       Date:  2016-04-15       Impact factor: 3.775

4.  Optical coherence tomographic angiography of choroidal neovascularization associated with central serous chorioretinopathy.

Authors:  Scott M McClintic; Yali Jia; David Huang; Steven T Bailey
Journal:  JAMA Ophthalmol       Date:  2015-10       Impact factor: 7.389

5.  Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy.

Authors:  E Smretschnig; S Hagen; C Glittenberg; R Ristl; I Krebs; S Binder; S Ansari-Shahrezaei
Journal:  Eye (Lond)       Date:  2016-03-11       Impact factor: 3.775

6.  Early response to the treatment of choroidal neovascularization complicating central serous chorioretinopathy: a OCT-angiography study.

Authors:  Riccardo Sacconi; Livia Tomasso; Eleonora Corbelli; Adriano Carnevali; Lea Querques; Stefano Casati; Francesco Bandello; Giuseppe Querques
Journal:  Eye (Lond)       Date:  2019-07-02       Impact factor: 3.775

7.  Polypoidal choroidal vasculopathy in patients aged less than 50 years: characteristics and 6-month treatment outcome.

Authors:  Young Suk Chang; Jae Hui Kim; Jong Woo Kim; Tae Gon Lee; Chul Gu Kim; Sung Won Cho
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-09-19       Impact factor: 3.117

8.  One-year outcomes of half-fluence photodynamic therapy combined with intravitreal injection of aflibercept for pachychoroid neovasculopathy without polypoidal lesions.

Authors:  Hidetaka Matsumoto; Ryo Mukai; Yuka Kikuchi; Masahiro Morimoto; Hideo Akiyama
Journal:  Jpn J Ophthalmol       Date:  2020-02-03       Impact factor: 2.447

9.  The use of optical coherence tomography angiography in pachychoroid spectrum diseases: a concurrent comparison with dye angiography.

Authors:  Sibel Demirel; Özge Yanık; Hilal Nalcı; Figen Batıoğlu; Emin Özmert
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-09-11       Impact factor: 3.117

10.  Response of neovascular central serous chorioretinopathy to an extended upload of anti-VEGF agents.

Authors:  Benedikt Schworm; Nikolaus Luft; Leonie F Keidel; Felix Hagenau; Christoph Kern; Tina Herold; Karsten U Kortuem; Siegfried G Priglinger; Jakob Siedlecki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-02-28       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.